Revance Therapeutics Inc (NASDAQ: RVNC), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities.
The downgrade of Revance is based on Allergan plc (NYSE: AGN)'s recently released data in Botox responders showing that 80 units of Botox 80 produced a more than 1-point improvement in 24 weeks in 39 percent of study patients, Ellis said in a Monday note. (See his track record here.)
Revance is testing RT002, daxibotulinumtoxinA injection, in a Phase 3 study for Glabellar Lines while also pursuing Phase 2 trials for cervical dystonia and plantar fasciitis.
Revance's RT002 showed similar improvement in about 42 percent of study population, the analyst said.
"AGN's data suggest that the longer duration of activity for RT002 may be partially or primarily due to a 'dose' effect," Ellis said.
Allergan's recent data minimizes the benefit of extended duration claims for RT002 vs. Botox, the analyst said.
The FDA requires a more than or equal to 2-point improvement, and none or mild on wrinkle severity, which both companies have not disclosed, he said.
JMP does not expect the companies to make 24-week claims.
"AGN can educate doctors on longer duration with higher doses at medical conferences, but its reps cannot legally promote longer duration directly to doctors," Ellis said.
The Price Action
Revance was down 8.28 percent at $23.55 at the close Monday, while Allergan was down 2.09 percent at $184.29.
Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Latest Ratings for RVNC
|Sep 2018||JMP Securities||Downgrades||Market Outperform||Market Perform|
|Mar 2018||Goldman Sachs||Initiates Coverage On||Buy|
View More Analyst Ratings for RVNC
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter
- The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.